

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13785-745005	Application No. <u>10/668,583</u> Not yet Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <u>Tsai et al.</u>	
		Filing Date <u>Herewith</u>	Group Art Unit <u>Unknown 1614</u>

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<u>JS</u>	AA	3,873,722	3/25/1975	Smythies			
	AB	5,015,740	05/14/1991	Kennis et al.			
	AC	5,051,448	09/24/1991	Shashoua			
	AD	5,061,721	10/29/1991	Cordi et al.			
	AE	5,112,863	05/12/1992	Hashimoto et al.			
	AF	5,187,171	02/16/1993	Cordi			
	AG	5,260,324	11/9/1993	Cordi et al.			
	AH	5,468,763	11/21/1995	Cordi et al.			
	AI	5,482,967	01/09/1996	Natsugari et al.			
	AJ	5,633,281	05/27/1997	Teall et al.			
	AK	5,837,730	11/17/1998	Javitt			
	AL	5,854,286	12/29/1998	Javitt et al.			
	AM	6,162,827	12/19/2000	Javitt			
	AN	6,355,681	03/12/2002	Javitt			
	AO	6,361,957	03/26/2002	Javitt			
<u>JS</u>	AP	US2002/0161048 A1	10/31/2002	Javitt			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<u>JS</u>	AQ	0 387 867 A1	09/19/90	Europe			XX	
	AR	0 432 039 A2	06/12/91	Europe			XX	
	AS	0 652 012 A1	05/10/95	Europe			XXX	
	AT	0 696 586 A1	02/14/96	Europe			XX	
	AU	JP 08026986A	01/30/96	Japan			XX	
	AV	JP 55 020747 A	02/14/80	Japan (Abstract)			XX	
<u>JS</u>	AW	DE 41 17 629 A1	12/03/92	Germany				XX

Examiner Signature <u>[Signature]</u>	Date Considered <u>3/23/04</u>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13785-745005	Application No. <u>10/668,583</u> Not yet Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <u>Tsai et al.</u>	
		Filing Date Herewith	Group Art Unit <u>Unknown 1614</u>


Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<u>JS</u>	AX	RU 2096044 C1	11/20/97	Russia	<u>/</u>	<u>/</u>	XX	
	AY	HU P9200192A	01/27/03	Hungary	<u>/</u>	<u>/</u>		XX
	AZ	WO 89/05144	06/15/89	PCT	<u>/</u>	<u>/</u>	XX	
	AAA	WO 97/20552	06/12/97	PCT	<u>/</u>	<u>/</u>	XX	
<u>JS</u>	ABB	WO 97/20553	06/12/97	PCT	<u>/</u>	<u>/</u>	XX	
	ACC							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<u>JS</u>	ADD	Barnes <i>et al.</i> , "A Rating Scale for Drug-Induced Akathisia" <i>British Journal of Psychiatry</i> 154:672-676, 1989.
	AEE	Bart <i>et al.</i> , "Efficacy and Tolerance of D-Cycloserine in Drug-Free Schizophrenic Patients" <i>Biological Psychiatry</i> 40:1298-1300, 1996.
	AFF	Baxter <i>et al.</i> , "D-Cycloserine, a Novel Cognitive Enhancer, Improves Spatial Memory in Aged Rats" <i>Neurobiology of Aging</i> 15:207-213, 1994.
	AGG	Baxter <i>et al.</i> , "Modulation of the NMDA Receptor Complex by D-Cycloserine" <i>CNS Drug Reviews</i> 1:74-90, 1995.
	AHH	Cascella <i>et al.</i> , "d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study" <i>Journal of Neural Transmission</i> 95:10-111, 1994.
	AII	Chessell <i>et al.</i> , "D-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain" <i>Brain Research</i> 565:345-348, 1991.
	AJJ	Contreras, "D-Serine Antagonized Phencyclidine- and MK-801-Induced Stereotyped Behavior and Ataxia" <i>Neuropharmacology</i> 29:291-293, 1990.
	AKK	Crane, "Cycloserine as an Antidepressant Agent" <i>The American Journal of Psychiatry</i> 115:1025-1026, 1959.
	ALL	Cutler <i>et al.</i> , "The Tolerability and Efficacy of Cycloserine in Alzheimer's Disease" <i>Am. Coll. Neuropsychopharmacol. Annual Meeting</i> , Puerto Rico, 1994.
	AMM	D'Souza <i>et al.</i> , "Glycine Site Agonists of the NMDA Receptor: A Review" <i>CNS Drug Reviews</i> 1:227-260, 1995.
	ANN	Falk <i>et al.</i> , "A Case Series of D-Cycloserine Added to Donepezil in the Treatment of Alzheimer's Disease" <i>J. Neuropsychiatry Clin. Neurosci.</i> 14:466-467, 2002.
	AOO	Fishkin <i>et al.</i> , "D-Cycloserine Attenuates Scopolamine-Induced Learning and Memory Deficits in Rats" <i>Behavioral and Neural Biology</i> 59:150-157, 1993.
	APP	Francis <i>et al.</i> , "A Glycine Site as Therapeutic Target" Institute of Neurology, Miriam Marks Department of Neurochemistry, London, WC1N, 1PJ, United Kingdom, pp. 184-188. <u>No date available</u>
<u>JS</u>	AQQ	Goff <i>et al.</i> , "D-Cycloserine Added to Clozapine for Patients With Schizophrenia" <i>Am. J. Psychiatry</i> 153:1628-1630, 1996.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13785-745005	Application No. <u>10/668,583</u> Not yet Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <u>Tsai et al.</u>	
		Filing Date Herewith	Group Art Unit <u>Unknown 1614</u>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ARR	Goff et al., "Dose-Finding Trial of D-Cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia" <i>Am. J. Psychiatry</i> 152:1213-1215, 1995.
	ASS	Hashimoto et al., "D-Alanine inhibits methamphetamine-induced hyperactivity in rats" <i>European Journal of Pharmacology</i> 202:105-107, 1991.
	ATT	Javitt et al., "Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse" <i>Psychopharmacology</i> 129:96-98, 1997.
	AUU	Javitt et al., "Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Uptake Inhibitor Glycyldodecylamide" <i>Neuropsychopharmacology</i> 17:202-204, 1997.
	AVV	Kay et al., "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia" <i>Schizophrenia Bulletin National Institute of Mental Health</i> 13:261-276, 1987.
	AWW	Kirkpatrick et al., "The Schedule for the Deficit Syndrome: An Instrument for Research in Schizophrenia" <i>Psychiatry Research</i> 30:119-123, 1989.
	AXX	Kumashiro et al., "Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases" <i>Brain Res.</i> 681:117-125, 1997.
	AYY	Leiderman et al., "Preliminary Investigation of High-Dose Oral Glycine in Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial" <i>Biological Psychiatry</i> , 39:213-215, 1996.
	AZZ	Lindenmayer et al., "Five-Factor Model of Schizophrenia Initial Validation" <i>The Journal of Nervous and Mental Disease</i> 182:631-638, 1994.
	AAAA	Lingjaerde et al., "The UKU side effects rating scale" <i>Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU)</i> ; pp. 81-94, 1986.
	ABBB	Malhotra et al., "NMDA receptor function and human cognition the effects of ketamine in healthy volunteers" <i>Neuropsychopharmacology</i> 14:301-307, 1996.
	ACCC	Matsuoka et al., "D-Cycloserine, a Partial Agonist at the Glycine Site Coupled to N-Methyl-D-aspartate Receptors, Improves Visual Recognition Memory In Rhesus Monkeys" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 278:891-897, 1996.
	ADDD	McKhann et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department ..." <i>Neurology</i> 34:939-944, 1984.
	AEEE	Monahan et al., "Characterization of a [³ H]Glycine Recognition Site as a Modulatory Site of the N-Methyl-D-Aspartate Receptor Complex" <i>Journal of Neurochemistry</i> 53:370-375, 1989.
	AFFF	Morrison and Boyd, "Carboxylic Acids," Chapter 23, pp. 822-823, in <i>Organic Chemistry</i> , Fifth ed. Boston: Allyn and Bacon, Inc. <u>(no date available)</u>
	AGGG	Nilsson et al., "Glycine and D-serine decrease MK-801-induced hyperactivity in mice" <i>J. Neural. Transm</i> 104:1195-1205, 1997.
	AHHH	Nishikawa et al., "PCP-induced abnormal behavior and c-fos gene expression in the brain as indices for neuroleptic-resistant symptoms of schizophrenia" <i>Folia Pharmacologica Japonica</i> , Patent Abstract XP-002117995, 1996.
	AIHH	Papp et al., "Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression" <i>European Journal of Pharmacology</i> 316:145-151, 1996.
	AJJJ	Patent Abstract; XP-002117996; JP55020747 A; "Antidepressant Drug Low Side Effect Contain Serine Salt Effect Component" 1980.
	AKKK	Patent Abstract; XP-002117997; JP08026986; "Anti-phencyclidine drugs contain D-serine esters of formula (I) or their salts as active agents" 1996.

Examiner Signature 	Date Considered <u>3/23/04</u>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13785-745005	Application No. 10/668,583 Not yet Assigned
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Tsai <i>et al.</i>	
		Filing Date Herewith	Group Art Unit Unknown 1614
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ALLL	Prous <i>et al.</i> , "D-Cycloserine" <i>Drugs of the Future</i> 19: 988-991, 1994.
	AMMM	Ramakers <i>et al.</i> , "The Impaired Long-Term Potentiation in the CA1 Field of the Hippocampus of Cognitive Deficient Microencephalic Rats is Restored by D-Serine" <i>Neuroscience</i> 54:49-60, 1993.
	ANNN	Ramakrishna <i>et al.</i> , "Betaine reverses toxic effects of aluminium: Implications in Alzheimer's disease (AD) and AD-like pathology" <i>Current Science</i> 75:1153-1156, 1998.
	AOOO	Randolph <i>et al.</i> , "D-Cycloserine Treatment of Alzheimer Disease" <i>Alzheimer Disease and Associate Disorders</i> 8:198-205, 1994.
	APPP	Riekkinen <i>et al.</i> , "The Effects of D-Cycloserine on Cognition in Experimental Models of Alzheimer's Disease" <i>Neurology</i> 43:A292; Abstract XP-0021178979. (no date available)
	AQQQ	Rimland, "Dimethylglycine (DMG), a nontoxic metabolite, and autism"; <i>Editor's Notebook</i> ; Abstract XP-002117993. (no date available)
	ARRR	Rockstroh <i>et al.</i> , "Effects of the Novel NMDA receptor antagonist SDZ EAA 494 on memory and attention in humans" <i>Psychopharmacology</i> 124:261-266, 1996.
	ASSS	Rosen <i>et al.</i> , "A new rating scale for Alzheimer's Disease" <i>The American Journal of Psychiatry</i> 141:1356-1364, 1984.
	ATTT	Russell, "A Multiple scoring method for the assessment of complex memory functions" <i>Journal of Consulting and Clinical Psychology</i> 43:800-809, 1975.
	AUUU	Schuster <i>et al.</i> , "D-Cycloserine reverse the working memory impairment of hippocampal-lesioned rats in a spatial learning task" <i>European Journal of Pharmacology</i> 224:97-98, 1992.
	AVVV	Simeon <i>et al.</i> , "d-Cycloserine Therapy of Psychosis by Symptom Provocation" <i>Comprehensive Psychiatry</i> 11:80-88, 1970.
	AWWW	Simpson <i>et al.</i> , "A Rating Scale for Extrapyramidal Side Effects" <i>Acta Psychiatr. Scand. Suppl.</i> 212:11-19, 1970.
	AXXX	Sirvio <i>et al.</i> , "D-Cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist" <i>Neuroscience Letters</i> 146:215-218, 1992.
	AYYY	Tanii <i>et al.</i> , "Effects of Allosteric Agonists for NMDA Receptor and Their Derivatives on PCP-Induced Abnormal Behaviors in Rat" National Institute of Neuroscience, NCNP, Kodaira; XP-002117991; Vol. 44, 1990.
	AZZZ	Tanii <i>et al.</i> , "Stereoselective Antagonism by Enantiomers of Alanine and Serine of Phencyclidine-Induced Hyperactivity, Stereotypy and Ataxia in the Rat" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 269:1040-1048, 1994.
	AAAAA	Temple <i>et al.</i> , "Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury" <i>Brain Research</i> 741: 246-251, 1996.
	ABBBB	Tsai <i>et al.</i> , "A Preliminary Study of D-Cycloserine Treatment in Alzheimer's Disease" <i>The Journal of Neuropsychiatry</i> 10:224-226, 1998.
	ACCCC	Tsai <i>et al.</i> , "Improved cognition in Alzheimer's Disease with Short-Term D-Cycloserine Treatment" <i>Am. J. Psychiatry</i> 156:467-469, 1999.
	ADDDD	Vamvakides, "Nootropic activity of glycinergic derivatives in relation to their dualistic effects on cerebral monoamines" <i>Boll. Chim. Farm.</i> 133:369-373, 1994.
	AEEEE	van Berckel <i>et al.</i> , "Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients" <i>Biol. Psychiatry</i> 40:1298-1300, 1996.

Examiner Signature 	Date Considered 3/23/04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	